Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 13.9
(17.0%)
HKD 13.9
(17.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -382.95 Million CNY | 36.4% |
| 2022 | -602.15 Million CNY | -2.83% |
| 2021 | -585.59 Million CNY | -7.85% |
| 2020 | -542.97 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -25.33 Million CNY | 0.0% |
| 2024 Q1 | -25.33 Million CNY | 73.76% |
| 2023 FY | -382.95 Million CNY | 36.4% |
| 2023 Q4 | -96.57 Million CNY | 0.0% |
| 2023 Q3 | -96.57 Million CNY | -1.76% |
| 2023 Q2 | -94.9 Million CNY | 0.0% |
| 2023 Q1 | -94.9 Million CNY | 42.41% |
| 2022 Q1 | -136.19 Million CNY | 8.07% |
| 2022 Q4 | -164.78 Million CNY | 0.0% |
| 2022 FY | -602.15 Million CNY | -2.83% |
| 2022 Q3 | -164.78 Million CNY | -20.99% |
| 2022 Q2 | -136.19 Million CNY | 0.0% |
| 2021 Q2 | -124.63 Million CNY | 0.0% |
| 2021 FY | -585.59 Million CNY | -7.85% |
| 2021 Q4 | -148.15 Million CNY | 0.0% |
| 2021 Q3 | -148.15 Million CNY | -18.87% |
| 2021 Q1 | -124.63 Million CNY | 0.0% |
| 2020 FY | -542.97 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 640.311% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 2320.006% |